Driving compliance in fully remote Alzheimer’s trials is complex, ICON Concierge Services makes it possible. In a pre-clinical study with 600+ participants and over 50 ePROs per patient, Concierge direct-to-patient serv...
In the News
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Encouraging patient participation in real world studies
Real world data is rapidly becoming the latest frontier for life sciences companies for supporting regulatory filings and conducting drug safety surveillance. ICON experts discuss the critical role of patients and advocacy groups in the June issue of Pharmaceutical Market Europe.
-
Improving access and reimbursement for specialty therapies
As specialty therapies move toward long-term maintenance use and as treatment times grow longer, payers are scrutinising the economic value more closely. ICON experts discuss how clinical development can better satisfy the evidence needs of HTA bodies and payers.
-
The evolution of real world studies
Real world evidence is not a new concept, but its influence on drug development decision-makers continues to increase. ICON expert Bill Row discusses how life sciences companies can maximise the use of real world data to support commercial success in this Pharmaceutical Market Europe (PME) article.
-
Embracing Digital Health
A thought leadership article by Vicki Anastasi, Matt McCarty and Marie McCarthy, published by the Journal of mHealth, on the skills and expertise needed to best use mHealth to transform clinical trials, thereby improving the efficacy of therapies in the real world and increasing pharma R&D productivity.
